Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

ABI-007-PST-001 is a Phase 1/2, multicenter, open-label, dose-finding study to assess the safety , tolerability, and preliminary efficacy of weekly nab-paclitaxel in pediatric patients with recurrent or refractory solid tumors (excluding brain tumors). The Phase 1 portion of the study, with a dose escalation design, ended and the recommended Phase 2 dose (RP2D) was determined as 240 mg/m\^2 intravenously (IV) in patients weighing > 10 kg and 11.5 mg/kg in patients weighing ≤ 10 kg, on Days 1, 8 and 15 of a 28-day cycle. The Phase 2 portion of the study will enroll additional patients at the RP2D into 1 of 3 solid tumor groups \[neuroblastomas, rhabdomyosarcomas, Ewing's sarcomas\]. Both phases of the study are open-label and conducted at multiple centers.

The Phase 2 is using a Simon 2-stage design to monitor patient enrollment for each group separately. The rhabdomyosarcoma group, neuroblastoma or Ewing's sarcoma groups did not reach the expected number of 2 responders out of 14 efficacy eligible patients. Consequently, the groups were stopped.

• nab-paclitaxel (Drug), also known as Abraxane: nab-paclitaxel 120-270 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle
• nab-paclitaxel (Drug), also known as Abraxane: IV infusion

Primary outcomes

• Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs) [DLT assessment period: For participants > 10 kg: the first 28-day cycle including Cycle 2 Day 1 predose evaluations; for participants ≤ 10 kg: the first two 28-day cycles including Cycle 3 Day 1 predose evaluations]: A DLT was defined as investigational product (IP)-related adverse events occurring during the DLT assessment period that led to treatment discontinuation or met one of the following criteria: - Common Terminology Criteria for Adverse Events (CTCAE) Grade (Gr) 3 or 4 nonhematologic toxicity (excluding transient transaminitis) - CTCAE Gr 3 or 4 nausea or vomiting that persisted > 5 days despite maximal anti-emetic treatment - CTCAE Gr 4 thrombocytopenia or anemia that persisted > 7 days or required transfusion > 7 days - CTCAE Gr 3 thrombocytopenia with bleeding - CTCAE Gr 4 uncomplicated neutropenia lasting > 7 days - Febrile neutropenia with confirmed bacterial infection - CTCAE Gr 3 hematologic toxicity requiring treatment (tx) delay > 21 days. Use of "..." in the table rows signifies the continuation of row title per the above list.
• Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) [Median treatment duration in Phase 1 was 7.0 weeks, with minimum and maximum duration of 1 and 49 weeks, respectively. Participants were followed for 28 days after discontinuing treatment for safety and monitoring of AEs.]: An adverse event (AE) was defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A serious AE (SAE) is any AE occurring at any dose that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. TEAEs were defined as AEs that began or worsened in severity on or after the date of the first dose of study drug and within 28 days of the date of the last dose of study drug. The severity of an AE was graded according to the CTCAE, Version 4.0.
• Phase 2: Overall Response Rate (ORR) [Median treatment duration in Phase 2 per group: Ewings Sarcoma = 14 weeks (3-31), Neuroblastoma = 7 weeks (3-23), Rhabdomyosarcoma = 5 weeks (1-13).]: Overall response rate was defined as the percentage of participants who achieved a complete response (CR; disappearance of all target lesions) or partial response (PR; at least a 30% decrease in the sum of diameters of target lesions) confirmed no less than 4 weeks after the criteria for response were first met using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. (For Phase 2 neuroblastoma participants who had both RECIST and Curie Score tumor evaluations, both tumor response results were considered and an overall response was derived.) Confidence interval was obtained using the Clopper-Pearson method.

Secondary outcomes

• Phase 1: ORR [Median treatment duration in Phase 1 was 7.0 weeks, with minimum and maximum duration of 1 and 49 weeks, respectively.]: Overall response rate was defined as the percentage of participants who achieved a complete response (CR; disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) confirmed no less than 4 weeks after the criteria for response were first met) using RECIST version 1.1 guidelines over the total number of participants available for the analysis. Confidence interval was obtained using the Clopper-Pearson method.
• Phase 1: Maximum Observed Concentration of Paclitaxel in Blood Plasma (Cmax) [Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)]
• Phase 1: Cmax - Dose-Normalized [Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)]
• Phase 1: Area Under the Plasma Concentration-Time Curve (AUC) [Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)]: Measurements include: AUC from time zero to the last measurable concentration (AUCt), AUC from time zero to 24 hours (AUC24), and AUC from time zero to infinity (AUCinf).
• Phase 1: AUC - Dose-Normalized [Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)]: Measurements include: AUC24 and AUCinf.
• Phase 1: Clearance (CL) [Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)]: Measurement of renal clearance from the body.
• Phase 1: CL - Body Surface Area (BSA)-Normalized [Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)]: Measurement of renal clearance from the body.
• Phase 1: Volume of Distribution (Vss) [Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)]
• Phase 1: Vss - BSA-Normalized [Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)]
• Phase 1 and 2 Population PK: Volume of Distribution of the Central Compartment (V1) [Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants < 6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)]: Population PK analysis was performed using nonlinear mixed effect modeling. The estimated allometric function for V1 was 0.888.
• Phase 1 and 2 Population PK: Maximum Elimination Rate From the Central Compartment (VMEL) [Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants < 6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)]: Population PK analysis was performed using nonlinear mixed effect modeling. The estimated allometric function for VMEL was 1.12.
• Phase 1 and 2 Population PK: Concentration in the Central Compartment at 50% of VMEL (KMEL) [Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants < 6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)]: Population PK analysis was performed using nonlinear mixed effect modeling.
• Phase 1 and 2 Population PK: Intercompartmental CL Between the Central Compartment and the First Peripheral Compartment (Q2) [Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants < 6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)]: Population PK analysis was performed using nonlinear mixed effect modeling. The estimated allometric function for Q2 was 1.12.
• Phase 1 and 2 Population PK: Intercompartmental CL Between the Central Compartment and the Second Peripheral Compartment (Q3) [Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants < 6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)]: Population PK analysis was performed using nonlinear mixed effect modeling. The estimated allometric function for Q3 was 1.12.
• Phase 1 and 2 Population PK: Volume of Distribution of the First Peripheral Compartment (V2) [Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants < 6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)]: Population PK analysis was performed using nonlinear mixed effect modeling. The estimated allometric function for V2 was 0.888.
• Phase 1 and 2 Population PK: Volume of Distribution of the Second Peripheral Compartment (V3) [Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants < 6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)]: Population PK analysis was performed using nonlinear mixed effect modeling. The estimated allometric function for V3 was 0.888.
• Phase 2: Duration of Response (DOR) [Median treatment duration in Phase 2 per group: Ewings Sarcoma = 14 weeks (3-31), Neuroblastoma = 7 weeks (3-23), Rhabdomyosarcoma = 5 weeks (1-13). Participants were followed until disease progression (if applicable) up to a maximum of 100.3 weeks.]: Duration of response was defined as the time from the date of the first response (CR/PR, using RECIST version 1.1 guidelines) to disease progression for participants with a confirmed CR or PR. Participants who did not have disease progression or had not died were censored at the time of their last disease assessment or at time of start of new anticancer therapy, whichever occurred first. (For Phase 2 neuroblastoma patients who had both RECIST version 1.1 and Curie Score tumor evaluations, both tumor responses results were considered and an overall response was derived.)
• Phase 2: Disease Control Rate (DCR) [Median treatment duration in Phase 2 per group: Ewings Sarcoma = 14 weeks (3-31), Neuroblastoma = 7 weeks (3-23), Rhabdomyosarcoma = 5 weeks (1-13).]: Disease control rate was defined as the percentage of participants who achieved either a stable disease maintained for ≥ 16 weeks or confirmed CR (confirmed no less than 4 weeks after criteria for response were first met) or confirmed PR (confirmed no less than 4 weeks after criteria for response were first met) over the total number of participants available for the analysis. Confidence interval was obtained using the Clopper-Pearson method.
• Phase 2: Progression-Free Survival (PFS) [Median treatment duration in Phase 2 per group: Ewings Sarcoma = 14 weeks (3-31), Neuroblastoma = 7 weeks (3-23), Rhabdomyosarcoma = 5 weeks (1-13). Participants were followed until disease progression (if applicable) up to a maximum of 100.3 weeks.]: PFS was defined as the time from the first dose date to the start of disease progression or participant death (any cause), whichever occurred first. Disease progression was classed as either a disease progression observed as a response assessment, or a disease progression or symptomatic deterioration at treatment/study discontinuation. Participants who did not have disease progression or had not died were censored at the last known time that the participant was progression free. Disease progression was considered according to RECIST version 1.1 for Phase 2 Ewing's sarcoma and rhabdomyosarcoma participants. (For Phase 2 neuroblastoma participants who had both RECIST 1.1 and Curie score tumor evaluations, both tumor responses results were considered and an overall response was derived.) Median PFS time was estimated through Kaplan-Meier methods. 95% confidence interval about the median time to PFS event was obtained using Greenwood's method.
• Phase 2: Kaplan-Meier Estimate of Overall Survival Rate at 1 Year [1 year]: Overall survival was defined as the time from the first dose date to date of death (any cause). Participants who were alive were censored at the last known time that the participant was alive.
• Phase 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) [Median treatment duration in Phase 2 per group: Ewings Sarcoma = 14 weeks (3-31), Neuroblastoma = 7 weeks (3-23), Rhabdomyosarcoma = 5 weeks (1-13). Participants were followed for 28 days after discontinuing treatment for safety and monitoring of AEs.]: An AE was defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A SAE is any AE occurring at any dose that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. TEAEs were defined as AEs that began or worsened in severity on or after the date of the first dose of study drug and within 28 days of the date of the last dose of study drug. The severity of the AEs was graded according to the Common Terminology Criteria for Adverse Events, Version 4.0. Participants were followed for 28 days after discontinuing treatment for safety and monitoring of AEs.

Sex: All, ages: 6 Months to 24 Years

Inclusion Criteria:

* Patients must meet all of the following criteria to be enrolled in the study:

  1. Patient has a confirmed solid tumor diagnosis according to the

     following:
     1. Phase 1: patient has a recurrent or refractory solid tumor that has

        progressed or did not respond to standard therapy, or for which no

        standard anticancer therapy exists
     2. Phase 2: patient has radiologically documented measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (for neuroblastoma, evaluable disease by 123\^I-metaiodobenzylguanidine \[MIBG\]/Curie score is also acceptable) in 1 of the following tumor types and has failed up to 3 lines of treatment: Group 1: neuroblastoma, Group 2: rhabdomyosarcoma; Group 3: Ewing's sarcoma.
  2. The patient has a Lansky/Karnofsky performance status score of ≥ 70%.
  3. The patient has adequate serum chemistry levels, evidenced by the

     following laboratory values
     1. aspartate aminotransferase (AST)/serum glutamic-oxaloacetric

        transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic

        pyruvate transaminase (SGPT) ≤ 2.5 × upper limit of normal range (ULN)
     2. Total bilirubin ≤ 1.5 × ULN
     3. Creatinine ≤ 1.5 × ULN
  4. The patient has adequate bone marrow function, evidenced by the

     following:
     1. Absolute neutrophil count ≥ 1.0 × 10\^9 cells/L
     2. Platelets ≥ 80 × 10\^9 cells/L (transfusion independent, defined as not

        receiving platelet transfusions within 7 days prior to laboratory sample). In the phase 2 portion, for patients with known bone marrow involvement, platelets ≥ 50 × 10\^9 cells/L
     3. Hemoglobin ≥ 8 g/dL (transfusion is permitted to fulfill this criterion).
  5. The patient (when applicable) or patient's parent(s) or legal guardian(s)

     understand(s) and voluntarily signed an informed consent document prior

     to any study-related assessments/procedures being conducted. Where

     locally applicable, the patient also understands and voluntarily provides

     his/her assent prior to any study-related assessments/procedures being

     conducted.
  6. Male patients of childbearing potential must use a condom during

     sexual intercourse and shall not father a child during the study and for 6 months after the last dose of study medication.
  7. Female patients of childbearing potential \[defined as all female

     patients ≥ 12 years old or who have reached menarche, whichever occurs

     first\] must have both of the following:

     a. Agree to the use of two physician-approved contraceptive methods

     simultaneously or practice complete abstinence while on study medication or for a longer period if required by regulations.

     i. True abstinence: When this is in line with the preferred and usual

     lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation,

     symptothermal, postovulation methods) and withdrawal are not

     acceptable methods of contraception.

     ii. Acceptable contraceptive methods include: oral, injectable, or

     implantable hormonal contraceptive; tubal ligation; intra-uterine device;

     barrier contraceptive with spermicide; or vasectomized partner) including

     at least one barrier method.

     b. Have negative serum pregnancy test result at screening confirmed by

     negative urine pregnancy dipstick within 72 hours prior to first dose of

     investigational product (if serum test occurred > 72 hours from first

     dose); pregnancy test with sensitivity of at least 25 mIU/mL.

     Exclusion Criteria:
     * The presence of any of the following will exclude a patient from enrollment:

  <!-- -->

  1. The patient has a primary brain tumor(s) or brain metastasis (unless metastasis is treated and stable for > 28 days). In patients who are symptomatic, a brain scan is required to exclude metastasis.
  2. The patient has received therapeutic dose chemotherapy or radiotherapy ≤ 21 days prior to start of investigational product.
  3. The patient has received maintenance dose chemotherapy (e.g., low dose cyclophosphamide) ≤ 7 days from the first dose of investigational product.
  4. The patient has received any investigational therapy ≤ 28 days prior to start of investigational product. Investigational therapy is defined as any medicinal product that is not approved in the country of treatment for any indication, adult or pediatric.
  5. The patient has received any biological therapy ≤ 7 days prior to the start of investigational product, or monoclonal antibody ≤ 3 half-lives or 28 days, whichever is shorter, prior to the first dose of investigational product.
  6. The patient has received any hematopoietic stem cell transplantation (HSCT) ≤ 3 months prior to start of investigational product.
  7. The patient has received allogeneic hematopoietic stem cell transplantation (HSCT) ≤ 3 months or autologous HSCT ≤ 21 days prior to start of investigational product.
  8. The patient has not recovered from the acute toxic effects of prior chemotherapy, radiation, or major surgery/significant trauma.
  9. The patient has had minor surgery ≤ 7 days from the start of study treatment (excluding the placement of central/peripheral lines, skin biopsy).
  10. The patient has a known history of stroke, myocardial infarction, peripheral vascular disease, or recent (within 3 months) uncontrolled deep venous thrombosis.
  11. The patient has a known history or current diagnosis of human immunodeficiency virus (HIV) infection, regardless of treatment status.
  12. The patient has an uncontrolled intercurrent illness including but not limited to ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy, symptomatic heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  13. The patient has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from participating in the study.
  14. The patient has any condition, including the presence of laboratory abnormalities, that places the patient at unacceptable risk if he/she were to participate in the study.
  15. The patient has any condition that confounds the ability to interpret data from the study.
  16. The patient or parent(s)/guardian(s) is/are unable to comply with the study visit schedule and other protocol requirements, in the opinion of the investigator.
  17. The patient has ≥ Grade 2 peripheral neuropathy by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) at screening.

Participant flow

Outcome results

• Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs) (Primary), Count of participants, Participants: Phase 1: Nab-Paclitaxel 120 mg/m^2 1; Phase 1: Nab-Paclitaxel 150 mg/m^2 0; Phase 1: Nab-Paclitaxel 180 mg/m^2 0; Phase 1: Nab-Paclitaxel 210 mg/m^2 0; Phase 1: Nab-Paclitaxel 240 mg/m^2 0; Phase 1: Nab-Paclitaxel 270 mg/m^2 1
• Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (Primary), Count of participants, Participants: Phase 1: Nab-Paclitaxel 120 mg/m^2 16; Phase 1: Nab-Paclitaxel 150 mg/m^2 8; Phase 1: Nab-Paclitaxel 180 mg/m^2 14; Phase 1: Nab-Paclitaxel 210 mg/m^2 11; Phase 1: Nab-Paclitaxel 240 mg/m^2 8; Phase 1: Nab-Paclitaxel 270 mg/m^2 7
• Phase 2: Overall Response Rate (ORR) (Primary), Number, percentage of participants: Phase 2: Ewing's Sarcoma 0 (0.0 to 24.7); Phase 2: Neuroblastoma 0 (0.0 to 23.2); Phase 2: Rhabdomyosarcoma 7.1 (0.2 to 33.9)
• Phase 1: ORR (Secondary), Number, percentage of participants: Phase 1: Nab-Paclitaxel 120 mg/m^2 0 (0.0 to 23.2); Phase 1: Nab-Paclitaxel 150 mg/m^2 0 (0.0 to 36.9); Phase 1: Nab-Paclitaxel 180 mg/m^2 0 (0.0 to 26.5); Phase 1: Nab-Paclitaxel 210 mg/m^2 0 (0.0 to 30.8); Phase 1: Nab-Paclitaxel 240 mg/m^2 12.5 (0.3 to 52.7); Phase 1: Nab-Paclitaxel 270 mg/m^2 14.3 (0.4 to 57.9)
• Phase 1: Maximum Observed Concentration of Paclitaxel in Blood Plasma (Cmax) (Secondary), Geometric mean, ng/mL: Phase 1: Nab-Paclitaxel 120 mg/m^2 3488 +/- 73.7; Phase 1: Nab-Paclitaxel 150 mg/m^2 5468 +/- 38.0; Phase 1: Nab-Paclitaxel 180 mg/m^2 5597 +/- 33.4; Phase 1: Nab-Paclitaxel 210 mg/m^2 5616 +/- 63.9; Phase 1: Nab-Paclitaxel 240 mg/m^2 7831 +/- 23.1; Phase 1: Nab-Paclitaxel 270 mg/m^2 8078 +/- 41.5
• Phase 1: Cmax - Dose-Normalized (Secondary), Geometric mean, ng/mL/[mg]: Phase 1: Nab-Paclitaxel 120 mg/m^2 23.3 +/- 87.5; Phase 1: Nab-Paclitaxel 150 mg/m^2 25.4 +/- 46.6; Phase 1: Nab-Paclitaxel 180 mg/m^2 27.3 +/- 47.3; Phase 1: Nab-Paclitaxel 210 mg/m^2 23.2 +/- 80.3; Phase 1: Nab-Paclitaxel 240 mg/m^2 28.2 +/- 48.7; Phase 1: Nab-Paclitaxel 270 mg/m^2 21.0 +/- 46.6
• Phase 1: Area Under the Plasma Concentration-Time Curve (AUC) (Secondary), Geometric mean, ng*h/mL: Phase 1: Nab-Paclitaxel 120 mg/m^2 7844 +/- 73.4; Phase 1: Nab-Paclitaxel 150 mg/m^2 10374 +/- 91.8; Phase 1: Nab-Paclitaxel 180 mg/m^2 9690 +/- 37.1; Phase 1: Nab-Paclitaxel 210 mg/m^2 11817 +/- 64.0; Phase 1: Nab-Paclitaxel 240 mg/m^2 12706 +/- 29.2; Phase 1: Nab-Paclitaxel 270 mg/m^2 11245 +/- 22.6
• Phase 1: AUC - Dose-Normalized (Secondary), Geometric mean, ng*h/mL/[mg]: Phase 1: Nab-Paclitaxel 120 mg/m^2 42.7 +/- 77.4; Phase 1: Nab-Paclitaxel 150 mg/m^2 41.6 +/- 87.0; Phase 1: Nab-Paclitaxel 180 mg/m^2 40.8 +/- 39.7; Phase 1: Nab-Paclitaxel 210 mg/m^2 43.3 +/- 63.6; Phase 1: Nab-Paclitaxel 240 mg/m^2 40.2 +/- 65.4; Phase 1: Nab-Paclitaxel 270 mg/m^2 25.4 +/- 26.1
• Phase 1: Clearance (CL) (Secondary), Geometric mean, L/h: Phase 1: Nab-Paclitaxel 120 mg/m^2 16.1 +/- 75.6; Phase 1: Nab-Paclitaxel 150 mg/m^2 20.3 +/- 101; Phase 1: Nab-Paclitaxel 180 mg/m^2 20.9 +/- 39.9; Phase 1: Nab-Paclitaxel 210 mg/m^2 15.4 +/- 25.4; Phase 1: Nab-Paclitaxel 240 mg/m^2 19.1 +/- 67.4; Phase 1: Nab-Paclitaxel 270 mg/m^2 31.9 +/- 35.0
• Phase 1: CL - Body Surface Area (BSA)-Normalized (Secondary), Geometric mean, L/h/m^2: Phase 1: Nab-Paclitaxel 120 mg/m^2 13.5 +/- 85.1; Phase 1: Nab-Paclitaxel 150 mg/m^2 12.5 +/- 99.3; Phase 1: Nab-Paclitaxel 180 mg/m^2 17.8 +/- 38.3; Phase 1: Nab-Paclitaxel 210 mg/m^2 14.6 +/- 72.3; Phase 1: Nab-Paclitaxel 240 mg/m^2 16.7 +/- 29.2; Phase 1: Nab-Paclitaxel 270 mg/m^2 21.8 +/- 28.4
• Phase 1: Volume of Distribution (Vss) (Secondary), Geometric mean, liters: Phase 1: Nab-Paclitaxel 120 mg/m^2 127 +/- 145; Phase 1: Nab-Paclitaxel 150 mg/m^2 266 +/- 78.3; Phase 1: Nab-Paclitaxel 180 mg/m^2 146 +/- 106; Phase 1: Nab-Paclitaxel 210 mg/m^2 89.8 +/- 45.1; Phase 1: Nab-Paclitaxel 240 mg/m^2 175 +/- 117; Phase 1: Nab-Paclitaxel 270 mg/m^2 446 +/- 17.6
• Phase 1: Vss - BSA-Normalized (Secondary), Geometric mean, L/m^2: Phase 1: Nab-Paclitaxel 120 mg/m^2 106 +/- 95.3; Phase 1: Nab-Paclitaxel 150 mg/m^2 164 +/- 78.4; Phase 1: Nab-Paclitaxel 180 mg/m^2 124 +/- 82.8; Phase 1: Nab-Paclitaxel 210 mg/m^2 84.9 +/- 49.7; Phase 1: Nab-Paclitaxel 240 mg/m^2 154 +/- 56.5; Phase 1: Nab-Paclitaxel 270 mg/m^2 304 +/- 29.0
• Phase 1 and 2 Population PK: Volume of Distribution of the Central Compartment (V1) (Secondary), Number, liters: PK Population 11.8
• Phase 1 and 2 Population PK: Maximum Elimination Rate From the Central Compartment (VMEL) (Secondary), Number, μg/h: PK Population 31983
• Phase 1 and 2 Population PK: Concentration in the Central Compartment at 50% of VMEL (KMEL) (Secondary), Number, μg/L: PK Population 951
• Phase 1 and 2 Population PK: Intercompartmental CL Between the Central Compartment and the First Peripheral Compartment (Q2) (Secondary), Number, L/h: PK Population 22.4
• Phase 1 and 2 Population PK: Intercompartmental CL Between the Central Compartment and the Second Peripheral Compartment (Q3) (Secondary), Number, L/h: PK Population 34.8
• Phase 1 and 2 Population PK: Volume of Distribution of the First Peripheral Compartment (V2) (Secondary), Number, liters: PK Population 545
• Phase 1 and 2 Population PK: Volume of Distribution of the Second Peripheral Compartment (V3) (Secondary), Number, liters: PK Population 45.3
• Phase 2: Duration of Response (DOR) (Secondary), Median, weeks: Phase 2: Ewing's Sarcoma ; Phase 2: Neuroblastoma ; Phase 2: Rhabdomyosarcoma 6.14 (6.14 to 6.14)
• 4 more outcome measures not shown.

Adverse events

Time frame: Median treatment duration in Phase 1 was 7.0 weeks, with minimum and maximum duration of 1 and 49 weeks, respectively. Median treatment duration in Phase 2 per group: Ewings Sarcoma = 14 weeks (3-31), Neuroblastoma = 7 weeks (3-23), rhabdomyosarcoma = 5 weeks (1-13).

Serious adverse events by term

Other adverse events by term

190 more terms not shown.

• Moreno L, Casanova M, Chisholm JC, Berlanga P, Chastagner PB, Baruchel S, Amoroso L, Gallego Melcon S, Gerber NU, Bisogno G, Fagioli F, Geoerger B, Glade Bender JL, Aerts I, Bergeron C, Hingorani P, Elias I, Simcock M, Ferrara S, Le Bruchec Y, Slepetis R, Chen N, Vassal G. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. Eur J Cancer. 2018 Sep;100:27-34. doi: 10.1016/j.ejca.2018.05.002. Epub 2018 Jun 21. PMID 29936064
• Results publication: Amoroso L, Castel V, Bisogno G, Casanova M, Marquez-Vega C, Chisholm JC, Doz F, Moreno L, Ruggiero A, Gerber NU, Fagioli F, Hingorani P, Melcon SG, Slepetis R, Chen N, le Bruchec Y, Simcock M, Vassal G. Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. Eur J Cancer. 2020 Aug;135:89-97. doi: 10.1016/j.ejca.2020.04.031. Epub 2020 Jun 15. PMID 32554315
• Results publication: Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. PMID 31401903

• Study Protocol (PDF, 2016-07-13)
• Statistical Analysis Plan (PDF, 2018-01-12)

• Ileana Elias, M.D., Study director, Celgene Corporation